---
title: "ADC Therapeutics Grants Stock Options to New Employees Under Inducement Plan"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/274558006.md"
datetime: "2026-02-02T21:07:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274558006.md)
  - [en](https://longbridge.com/en/news/274558006.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274558006.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/274558006.md) | [繁體中文](https://longbridge.com/zh-HK/news/274558006.md)


# ADC Therapeutics Grants Stock Options to New Employees Under Inducement Plan

ADC Therapeutics SA has granted options to purchase a total of 308,000 common shares to seven new employees. The options will vest 25% on the first anniversary of the grant date, with the remaining shares vesting in equal monthly installments over the following three years, becoming fully vested after four years, contingent on continued employment. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADC Therapeutics SA published the original content used to generate this news brief on February 02, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### 相关股票

- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-CN/quote/BBH.US.md)
- [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-CN/quote/XLV.US.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-CN/quote/BIB.US.md)
- [iShares US Pharma (IHE.US)](https://longbridge.com/zh-CN/quote/IHE.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-CN/quote/IBBQ.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-CN/quote/XBI.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-CN/quote/IBB.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-CN/quote/PBE.US.md)
- [iShares Global Healthcare (IXJ.US)](https://longbridge.com/zh-CN/quote/IXJ.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-CN/quote/SBIO.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-CN/quote/FBT.US.md)
- [VG Health (VHT.US)](https://longbridge.com/zh-CN/quote/VHT.US.md)
- [ADC Therapeutics SA (ADCT.US)](https://longbridge.com/zh-CN/quote/ADCT.US.md)
- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-CN/quote/ARKG.US.md)

## 相关资讯与研究

- [Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis | ACRS Stock News](https://longbridge.com/zh-CN/news/279581540.md)
- [Pfizer announces positive topline phase 2 results for next-generation CDK4 inhibitor, atirmociclib, in second-line metastatic breast cancer](https://longbridge.com/zh-CN/news/279429425.md)
- [Novartis Raises $11 Billion to Fund Avidity Biosciences Deal](https://longbridge.com/zh-CN/news/279380374.md)
- [Red Light Holland Deploys Kala Bio AI Platform to Advance Psilocybin Drug PEX010](https://longbridge.com/zh-CN/news/279611034.md)
- [Vanderbilt Report: Artelo Biosciences Expands Into $16.3 Billion Glaucoma Market With Fully Funded Clinical Study | ARTL Stock News](https://longbridge.com/zh-CN/news/279594805.md)